Barclays raised the firm’s price target on McKesson to $571 from $537 and keeps an Overweight rating on the shares. The company’s fiscal Q3 featured puts and takes, with the headline beat and operational raise offset by a high bar and reiterated U.S. pharma profit growth, the analyst tells investors in a research note. The firm expects a mild pullback in shares today, but would be opportunistic on any weakness.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MCK: